As the world becomes more accepting of medicinal cannabis, hemp has been another big winner in terms of marketability which has led nutraceuticals company Live Verdure (ASX: LV1) to the United States which is the world’s largest market for such products. Owners of the hemp-based food brands “13 Seeds” and “8 Seeds” which originate from
Read More
If Australians have reservations about the use of medicinal cannabis to cure their ailments, there will soon be a low-cost option to trial cannabis products, with Althea Group (ASX: AGH) to launch a new range of low dosage oils to give first-time users an affordable entry point. The new ‘flexi’ cannabis oil products, as the
Read More
Having developed a thriving telehealth business that has seen significant uptake from patients seeking medicinal cannabis solutions, Epsilon Healthcare (ASX: EPN) is set to expand into retail locations for in-clinic consultations. While the progressive healthcare provider moves in the opposite direction to other medical clinics which were forced to adopt telehealth during the pandemic, telehealth
Read More
Medicinal cannabis company ECS Botanics (ASX: ECS) is quickly growing its international sales pipeline following their acquisition of Murray Meds last month, securing UK pharmaceuticals company The Armour Group on a 3-year export deal. The agreement will be for the sale, export and distribution of medicinal cannabis products in the UK for clinical trials initially,
Read More
Pharmaceuticals company Emyria (ASX: EMD) is set to commence the regulatory process of registering their cannabinoid-based medicine EMD-003 as a treatment to reduce symptoms of mental health disorders, leveraging extensive data gathered from their network of clinics. Initial evidence collected by Emyria’s subsidiary Emerald Clinics has identified an unmet need by targeting the treatment of
Read More
Medicinal cannabis and research company Althea Group (ASX: AGH) has become the first Australian producer of commercial cannabis products to be granted the required licenses in Germany for sales and distribution. With the licences, Althea expects their first shipment of their Australian-made medicinal cannabis extract products to take place in December 2020. The licenses were
Read More